Q2FY25 Result Update

BUY

Sun Pharma's Q2FY25 earnings came in slightly below expectations. Revenue reached INR 132.9 bn, reflecting a 9% YoY and 5% QoQ growth, driven primarily by robust performance in the US formulations segment. EBITDA rose significantly by 23.9% YoY and 9.2% QoQ to INR 39.4 bn, with margins expanding by 356 bps YoY and 112 bps QoQ to 29.6%. Adjusted PAT increased 28% YoY and 7.2% QoQ to INR 30.4 bn. The company aims for a goof topline growth this year, alongside a planned increase in R&D investment driven by specialty portfolio.

- India formulation business: The India formulation business contributed ~32% of total sales, growing by 11% YoY and 2.9% QoQ to INR 42.6 bn, primarily driven by volume growth. Market share increased to 8.1%, up from 7.7% the previous year. During the quarter, Sun Pharma launched 14 new products and continued to outpace IPM growth across major therapies. Looking ahead, the India business is expected to grow either in line with or slightly above IPM growth, projected to be in the high single digits for FY25.
- US formulation business: The US business represented 33% of total sales, reaching INR 43.3 bn with strong growth of 21.9% YoY and 11.3% QoQ, mainly driven by an expanding specialty products portfolio. The U.S. specialty business has shown robust growth, driven by new product launches and a strong prescription trend. Sun launched two generic products during the quarter, contributing to its overall sales performance.
- Emerging Markets & RoW: Emerging markets contributed 18% of sales, with marginal growth of 4.6% YoY and 3.5% QoQ. Meanwhile, the Rest of World (RoW) segment experienced a slight 2.2% YoY decline but grew 5.2% QoQ. Performance in major markets has been strong in local currency terms.
- Margin Profile: Gross margin expanded by 259 bps YoY and 87 bps QoQ, while EBITDA margin saw an increase of 356 bps YoY and 112 bps QoQ. R&D expenses for the quarter were INR 7,929 mn, representing 6% of sales. The company maintains a strong specialty product pipeline, with seven molecules currently in clinical trials. For FY25, management projects R&D expenses will account for 7-8% of total revenue, with a significant portion allocated to the specialty portfolio.
- Outlook & Valuation: The company's growth is anticipated to be fueled by a shift in its product mix toward the specialty portfolio, an improved margin profile, and continued outperformance of the India business relative to IPM. Introducing FY27E estimates, we expect these factors to support Revenue/EBITDA/PAT growth at a CAGR of 11.5%/13.9%/19.3% from FY24-27E. Valuing the stock based on Sep-FY27E EPS with an assigned PE of 32x, we set a target price of INR 2,036 and maintain a BUY rating.

Financial Snapshot

Year end: March	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenue (INR Mn.)	3,86,545	4,38,857	4,84,968	5,35,253	5,98,160	6,71,954
Gross Profit (INR Mn.)	2,83,029	3,32,235	3,78,342	4,20,921	4,69,547	5,27,844
EBITDA (INR Mn.)	1,03,977	1,16,468	1,30,231	1,48,303	1,70,828	1,92,228
EBITDA Margin (%)	26.9	26.5	26.9	27.7	28.6	28.6
Adj. EPS (INR)	28.1	36.0	41.7	50.2	59.5	67.8

Source: Company, CEBPL

Choice

	Oct 29, 2024
CMP (Rs)	1,903
Target Price (Rs)	2,036
Potential Downside (%)	7.0
*CMP as on 28 th Oct 2024	

Company Info

BB Code	SUNP IN EQUITY
ISIN	INE044A01036
Face Value (Rs.)	1
52 Week High (Rs.)	1,960
52 Week Low (Rs.)	1,069
Mkt Cap (Rs bn.)	4,564.9
Mkt Cap (\$ bn.)	54.3
Shares o/s (Mn.)/F.Float (%)	2399/45
TTM EPS (Rs)	46.1
EPS FY27E (Rs)	67.8


Shareholding Pattern (%)

	Sep-24	Jun-24	Mar-24
Promoters	54.48	54.48	54.48
FII's	18.01	17.23	17.72
DII's	18.48	19.17	18.71
Public	9.03	9.11	9.08

Relative Performance (%)

YTD	3Y	2Y	1Y
BSE Healthcare	74.0	83.7	59.2
Sun Pharma	135.6	92.2	71.2

Rebased Price Performance



Deepika Murarka, Analyst

Email: deepika.murarka@choiceindia.com Ph: +91 22 6707 9513

Maitri Sheth, Analyst

Email: maitri.sheth@choiceindia.com Ph: +91 22 6707 966

Quarterly performance					
Particulars (Rs. in Mn.)	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)
Revenue	1,32,914	1,21,924	9.0	1,26,527	5.0
Cost of Goods Sold	26,942	27,871	(3.3)	26,754	0.7
Gross Margin (%)	79.7	77.1	258.9 bps	78.9	87.5 bps
Employee Expenses	24,777	23,644	4.8	24,546	0.9
EBITDA	39,390	31,794	23.9	36,076	9.2
EBITDA Margin (%)	29.6	26.1	355.9 bps	28.5	112.3 bps
Depreciation	6,259	6,328	(1.1)	6,551	(4.5)
EBIT	36,670	28,402	29.1	34,850	5.2
Interest	692	493	40.3	615	12.4
РВТ	35,979	27,909	28.9	34,235	5.1
Тах	5,672	3,901	45.4	5,523	2.7
РАТ	30,402	23,755	28.0	28,356	7.2
PAT Margin (%)	22.9	19.5	339.0	22.4	46.2 bps
EPS	12.7	9.9	28.0	11.8	7.2

Source: Company, CEBPL

Geographical Performance

Rs. In Mn.	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)
India Formulation	42,652	38,425	11.0	41,445	2.9
% of sales	32.1	31.5		32.8	
US Formulation	43,274	35,504	21.9	38,894	11.3
% of sales	32.6	29.1		30.7	
Emerging Market	24,519	23,449	4.6	23,695	3.5
% of sales	18.4	19.2		18.7	
ROW Formulation	16,633	17,000	(2.2)	15,814	5.2
% of sales	12.5	13.9		12.5	
API	5,338	4,972	7.4	4,946	7.9
% of sales	4.0	4.1		3.9	
Other	498	2,573	(80.7)	1,734	(71.3)
% of sales	0.4	2.1		1.4	
Total Sales	1,32,914	1,21,924	9.0	1,26,527	5.0

Source: Company, CEBPL

CEBPL Estimates vs Actual

Rs. In Mn.	Actual	CEBPL Estimates	% Change
Sales	1,32,914	1,34,244	(1.0)
EBITDA	39,390	39,735	(0.9)
EBITDA Margin (%)	29.6	29.6	4 bps
PAT	30,402	32,208	(5.6)
EPS	12.7	13.4	(5.6)

Source: Company, CEBPL

Change in estimates for FY25E & FY26E

Income Statement	FY25E					FY27E	
(INR Mn.)	New	Previous	Dev. (%)	New	Previous	Dev. (%)	New
Net sales	5,35,253	5,30,965	0.8	5,98,160	5,90,924	1.2	6,71,954
EBITDA	1,48,303	1,41,288	5.0	1,70,828	1,65,320	3.3	1,92,228
EBITDA margin(%)	27.7	26.6	110	28.6	28.0	58	28.6
РАТ	1,20,445	1,14,134	5.5	1,42,692	1,37,601	3.7	1,62,667
EPS	50.2	47.6	5.5	59.5	57.4	3.7	67.8

Management Call - Highlights

India Business

 Growth is largely driven by volumes and new product launches, while IPM growth is primarily price-led.

US Business (including Taro Pharma)

- The US specialty business showed continued YoY growth, with strong underlying business and prescription trends.
- Sun also launched 2 generic products in the US during the quarter.

Emerging Markets and RoW


- Emerging markets saw a 5% YoY underlying growth in constant currency terms.
- The company's focus for Emerging Market remains on expanding in Brazil, Romania, South Africa, Russia, and Mexico.
- RoW segment declined due to price cuts in Japan, with management expecting this
 pressure to continue in the upcoming quarters.
- Initial traction for the recently launched product in China has been promising, with expectations for it to become a significant contributor over time.

Global Specialty

- The company entered a global licensing agreement to commercialize Fibromun, a specialty product from Phylogeny.
- Ilumya's phase two pediatric study may potentially target a new patient population, depending on phase two data outcomes.
- Clinical trials for the obesity molecule GL0034 are on track, with Sun expecting approvals in regulated markets first.


Others

- A decline in Winlevi prescriptions was noted, although QoQ improvement has since been observed.
- Increased selling and distribution expenses, particularly in the US and emerging markets, led to a sequential rise in other expenses.
- Plans are underway to utilize strong cash reserves for potential strategic acquisitions aligned with specialty and therapeutic priorities.
- Consolidated R&D investments reached INR 7,929 mn in Q2FY25, or 6% of sales, with specialty R&D accounting fro 38% of total.
- R&D efforts span both specialty and generic businesses, supporting pipeline growth across the US, Emerging Markets, RoW, and India.
- The specialty R&D pipeline includes 7 molecules in clinical trials.
- The US portfolio includes 538 approved ANDAs, with 105 ANDAs (28 tentative approvals) pending FDA review, and 51 approved NDAs with 13 pending. In Q2, 3 ANDAs were filed, 1 ANDA and 1 NDA received approval.
- Full-year R&D expenditure is projected at 7-8% of revenue.




India Formulation Revenue (Rs. mn) and QoQ Growth (%)

Source: Company, CEBPL



Source: Company, CEBPL




Source: Company, CEBPL

US Formulation Revenue (Rs. mn) and QoQ Growth (%)




Source: Company, CEBPL

Gross Profit (Rs. mn) and Margin (%)




Source: Company, CEBPL

Adj. PAT (Rs. mn) and Margin (%)



Source: Company, CEBPL


Revenue (Rs. mn) and QoQ Growth (%)




Revenue (Rs. mn) and YoY Growth (%)

EBITDA (Rs. mn) and Margin (%)


ROE (%) and ROIC (%)



Source: Company, CEBPL




Adj. PAT (Rs. mn) and Margin (%)



Source: Company, CEBPL

1 Year Forward PE Band



Income statement (Consolidated in INR Mn.)

Particular	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenue	3,86,545	4,38,857	4,84,968	5,35,253	5,98,160	6,71,954
Gross profit	2,83,029	3,32,235	3,78,342	4,20,921	4,69,547	5,27,844
EBITDA	1,03,977	1,16,468	1,30,231	1,48,303	1,70,828	1,92,228
Depreciation	21,437	25,294	25,566	25,753	25,168	26,268
EBIT	91,755	97,519	1,18,207	1,43,960	1,69,586	1,92,838
Other income	9,215	6,345	13,542	21,410	23,926	26,878
Interest expense	1,274	1,720	2,385	1,553	1,243	994
РВТ	44,813	94,084	1,10,879	1,42,406	1,68,343	1,91,844
Adj. PAT	67,435	86,296	1,00,065	1,20,445	1,42,692	1,62,667
Adj. EPS (INR)	28.1	36.0	41.7	50.2	59.5	67.8

Balance sheet (Consolidated in INR Mn.)


Particular	FY22	FY23	FY24	FY25E	FY26E	FY27E
Net worth	5,10,661	5,93,155	6,71,060	7,67,812	8,86,711	10,25,585
Borrowings	12,903	68,859	32,737	21,279	17,023	13,618
Trade Payables	44,793	56,815	56,533	64,524	73,746	82,844
Other non-current liabilities	10,515	9,612	10,689	12,256	13,514	14,990
Other current liabilities	1,19,126	78,995	83,611	98,328	1,12,390	1,25,747
Total Net Worth & liabilities	6,97,999	8,07,436	8,54,629	9,64,198	11,03,384	12,62,784
Net Block	1,03,714	1,03,904	1,01,923	63,694	49,526	34,257
Capital WIP	7,975	9,634	11,077	11,077	11,077	11,077
Goodwill & intangible assets	1,25,777	1,80,396	1,72,652	1,76,652	1,80,652	1,84,652
Investments	1,28,486	1,48,301	1,50,258	1,86,412	2,49,672	2,79,927
Trade Receivables	1,05,929	1,14,385	1,12,494	1,29,047	1,47,492	1,65,687
Cash & Bank	50,334	57,703	1,05,207	1,48,243	1,77,300	2,71,962
Other non-current assets	58,237	60,095	69,814	70,854	72,270	73,303
Other current assets	1,17,548	1,33,019	1,31,204	1,78,218	2,15,396	2,41,917
Total Assets	6,97,999	8,07,436	8,54,629	9,64,198	11,03,384	12,62,784

Cash Flows (INR Mn.)	FY22	FY23	FY24	FY25E	FY26E	FY27E
CFO	89,845	49,593	1,21,350	1,63,466	1,39,745	1,68,637
Сарех	(14,950)	(20,856)	(22,018)	(53,155)	(78,260)	(45,255)
FCFF	74,895	28,738	99,332	(41,305)	(32,429)	(28,719)
CFI	(57,247)	(79,437)	(16,920)	(13,000)	(11,000)	(11,000)
CFF	(51,935)	23,761	(67,101)	1,50,466	1,28,745	1,57,637

Choice

Growth Ratios (%)	FY22	FY23	FY24	FY25E	FY26E	FY27E
Revenues	15.4	13.5	10.5	10.4	11.8	12.3
Gross Profit	14.1	17.4	13.9	11.3	11.6	12.4
EBITDA	22.4	12.0	11.8	13.9	15.2	12.5
EBIT	26.6	6.3	21.2	21.8	17.8	13.7
РВТ	60.1	109.9	17.9	28.4	18.2	14.0
Adj. PAT	5.1	28.0	16.0	20.4	18.5	14.0
Margins (%)						
Gross Profit	73.2	75.7	78.0	78.6	78.5	78.6
EBITDA	26.9	26.5	26.9	27.7	28.6	28.6
EBIT	23.7	22.2	24.4	26.9	28.4	28.7
РВТ	11.6	21.4	22.9	26.6	28.1	28.6
Tax rate	24.0	9.0	13.0	15.0	15.0	15.0
Adj. PAT	17.4	19.7	20.6	22.5	23.9	24.2
Profitability (%)						
ROE	14.0	15.4	15.7	16.4	16.8	16.4
ROIC	15.9	19.7	18.4	20.1	21.7	21.2
ROCE	18.6	15.5	17.7	19.1	19.5	19.2
Financial leverage (x)						
Pre-tax OCF/EBITDA	1.0	0.5	1.0	1.2	1.0	1.0
OCF / Net profit	1.3	0.6	1.2	1.4	1.0	1.0
EV/EBITDA	38.0	34.4	33.3	35.8	31.7	22.3
Earnings						
EPS (Rs.)	28.1	36.0	41.7	50.2	59.5	67.8
Shares outstanding	2399.3	2399.3	2399.3	2399.3	2399.3	2399.3
Working Capital (days)						
Inventory days	85	87	74	80	83	83
Receivable days	101	96	86	88	90	90
Creditor days	42	47	43	44	45	45
Working Capital Days	143	137	118	124	128	128
Source: Company CERPI						

Historical recommendations and target price: Sun Pharma Industries



Sun Pharma Industries			
1. 30-07-2021	OUTPERFORM	Target Price Rs.909	
2. 29-10-2021	OUTPERFORM	Target Price Rs.924	
3. 02-02-2022	ADD	Target Price Rs.1,013	
4. 31-05-2022	ADD	Target Price Rs.983	
5. 01-08-2022	ADD	Target Price Rs.1,067	
6. 02-11-2022	ADD	Target Price Rs.1,162	
7. 01-02-2023	ADD	Target Price Rs.1,142	
8. 29-05-2023	OUTPERFORM	Target Price Rs.1,152	
9. 04-08-2023	ADD	Target Price Rs.1,246	
10.02-11-2023	ADD	Target Price Rs.1,272	
11. 30-01-2024	ADD	Target Price Rs.1,524	
12.23-05-2024	SELL	Target Price Rs. 1,412	
13.02-08-2024	BUY	Target Price Rs.1,835	
14. 29-10-2024	BUY	Target Price Rs.2,036	

Institutional Research Team			
Kripashankar Maurya	AVP - Institutional Research – Automobiles/Defence/Healthcare	kripashankar.maurya@choiceindia.com	+91 22 6707 9949
CA Vatsal Vinchhi	Analyst - Information Technology	vatsal.vinchhi@choiceindia.com	+91 22 6767 9224
Deepika Murarka	Analyst - Pharmaceuticals	deepika.murarka@choiceindia.com	+91 22 6707 9513
Vijay Singh Gaur	Analyst - BFSI	vijay.gour@choiceindia.com	+91 22 6707 9422
Ashutosh Murarka	Associate – Cement / Building Material	ashutosh.murarka@choiceindia.com	+91 22 6707 9442
Putta Ravi Kumar	Associate - Goods & Defence	ravi.putta@choiceindia.com	+91 22 6707 9908
Aayush saboo	Associate – Real Estate	aayush.saboo@choiceindia.com	+91 22 6707 9811
Maitri Sheth	Associate – Pharmaceuticals	maitri.sheth@choiceindia.com	+91 22 6707 9811
Bharat Kumar Kudikyala	Associate – Cement / Building Material	bharat.kudikyala@choiceindia.com	+91 22 6707 9798
Heet Chheda	Associate – Automobile	heet.chheda@choiceindia.com	+91 22 6707 9422
CHONCE RATING DISTRIBUTION	R Vice President Onetitational Sales	sheetal.murarka@choiceindia.com	+91 22 6707 9857
Nitesh Jalan	AVP – Institutional Sales	nitesh.jalan@choiceindia.com	+91 22 6707 9877 /878 /879
DUTPERFORM The security is expec	ted to generate more than 25% returns over the next 12 mo	nths	•

	The security is expected to generate more than 25% returns over the next 12 months
BUY	The security is expected to generate greater than 5% to less than 25% returns over the next 12 months
REDUCE	The security expected to show downside or upside returns by 0% to 5% over the next 12 months
SELL	The security expected to show Below 0% next 12 months

Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id - Prashant.salain@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited. The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include guality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person

placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment

/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide

for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Yester performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding

taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this "Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever. Find (Choice Equity Broking Pvt. Ltd.—Research Analyst] [NH CHB] | Capital IQ | Email: institutional.equities@choiceindia.com | Ph: +91 22 6707 9919

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" equires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

Disclosures of Interest (Additional):

- 1. "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. "CEBPL" its research Analyst, or its associates or relatives of the research analyst
- affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the
 research report.
- 4. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 6. "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in
- this report."CEBPL, or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- CEBPL research analyst has not served as an Officer. Director, or employee of the company (ies) covered in the Research report.
- "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. www. https://choiceindia.com/research-listing

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given below

Sr. No.	Particulars	
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given below